The first efficacy endpoint was improve from baseline MADRS score. This short-time period study found that, compared to intranasal placebo additionally oral antidepressant, intranasal esketamine together with an oral antidepressant considerably improved depressive indicators soon after 4 weeks by a necessarily mean difference of 4 points over the M